Previous 10 | Next 10 |
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...
Updating the progress of its clinical pipeline ahead of its first Pipeline and Platform Day, Rubius Therapeutics (NASDAQ:RUBY) said that additional data from its early-stage trial for off-the-shelf cellular therapy candidate RTX-240 are expected in Q1 2022. RTX-240 is undergoing a Phase 1 tri...
Highly Versatile and Programmable RED PLATFORM Enables Multiple Modalities to Target Different Immune Pathways Across a Range of Diseases Demonstrated Tolerance Induction with Bystander Suppression in Type 1 Diabetes Preclinical Program with Findings Translatable to Multiple T Cell-Me...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatme...
CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatme...
CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatme...
CAMBRIDGE Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatmen...
U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for RTX-224, Rubius’ Third Oncology Candidate Clinical Results Expected by Year-End or First Quarter 2022 in Phase 1 Trials of Single-Agent RTX-240 in Advanced Solid Tumors and Relapsed/Refractory...
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the tr...
News, Short Squeeze, Breakout and More Instantly...
Rubius Therapeutics Inc. Company Name:
RUBY Stock Symbol:
OTCMKTS Market:
Rubius Therapeutics Inc. Website:
iClick Interactive Asia Group Limited (ICLK) is expected to report for quarter end 2023-09-30 Applied Minerals Inc (AMNL) is expected to report for quarter end 2023-09-30 Banco Do Brasil S.A. ADR (BDORY) is expected to report for Q3 2023 Rubius Therapeutics Inc. (RUBY) is expected to ...
American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...